ACEI联合恩格列净治疗早中期糖尿病肾病的疗效观察  

Efficacy observation of ACEI combined with empagliflozin in the treatment of early and middle stage of diabetic nephropathy

作　　者：周飞霏 ZHOU Fei-fei(First Department of Internal Medicine,Dahua Group Co.,Ltd.Hospital,Dalian 116033,China)

机构地区：[1]大化集团责任有限公司医院内一科,116033

出　　处：《中国现代药物应用》2023年第12期98-101,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探讨血管紧张素转换酶抑制剂(ACEI)联合恩格列净治疗早中期糖尿病肾病的疗效。方法86例早中期糖尿病肾病患者,以奇偶法分为实验组与常规组,各43例。常规组采用常规疗法,实验组采用ACEI联合恩格列净治疗。比较两组疗效、治疗前后尿肾病相关指标[尿微量白蛋白(mALB)、尿白蛋白与肌酐比(UACR)、尿N-乙酰-β-D-葡萄糖苷酶(NAG)]、血糖指标(空腹血糖、餐后2 h血糖、糖化血红蛋白)。结果实验组治疗总有效率95.3%高于常规组的79.1%,差异有统计学意义(P<0.05)。治疗后,两组NAG、UACR、mALB均较治疗前下降,且实验组NAG(14.04±4.51)U/L、UACR(30.34±5.21)mg/g、mALB(29.90±6.86)mg/L低于常规组的(16.69±5.47)U/L、(54.35±10.28)mg/g、(35.33±8.28)mg/L,差异有统计学意义(P<0.05)。治疗后,两组空腹血糖、餐后2 h血糖、糖化血红蛋白均较治疗前降低,且实验组空腹血糖(5.42±0.28)mmol/L、餐后2 h血糖(6.42±0.21)mmol/L、糖化血红蛋白(6.31±1.31)%低于常规组的(6.02±0.41)mmol/L、(9.13±1.52)mmol/L、(7.82±1.03)%,差异有统计学意义(P<0.05)。结论ACEI联合恩格列净治疗早中期糖尿病肾病,可有效改善患者临床症状与尿肾病指标,还能控制患者血糖值处于稳定状态,适合临床深入研究与推广应用。Objective To discuss the efficacy of angiotensin converting enzyme inhibitor(ACEI)combined with empagliflozin in the treatment of early and middle stage of diabetic nephropathy.Methods A total of 86 patients with early and middle stage of diabetic nephropathy were divided into experimental group and conventional group by parity method,with 43 cases in each group.The conventional group was treated with conventional therapy,and the experimental group was treated with ACEI and empagliflozin.Both groups were compared in terms of therapeutic effect,urinary nephropathy related indexes[microalbumin(mALB),urinary albumin to creatinine ratio(UACR),N-acetyl-β-D-glucosaminidase(NAG)]and blood glucose indexes(fasting blood glucose,2 h postprandial glucose,glycosylated hemoglobin)before and after treatment.Results The total effective rate of 95.3%in the experimental group was higher than that of 79.1%in the conventional group,and the difference was statistically significant(P<0.05).After treatment,NAG,UACR and mALB decreased in both groups compared with those before treatment in this group;the experimental group had NAG of(14.04±4.51)U/L,UACR of(30.34±5.21)mg/g,and mALB of(29.90±6.86)mg/L,which were lower than those of(16.69±5.47)U/L,(54.35±10.28)mg/g,and(35.33±8.28)mg/L in the conventional group;the differences were statistically significant(P<0.05).After treatment,the fasting blood glucose,2 h postprandial glucose and glycosylated hemoglobin in both groups were lower than those before treatment in this group;the experimental group had fasting blood glucose of(5.42±0.28)mmol/L 2 h postprandial glucose of(6.42±0.21)mmol/L and glycosylated hemoglobin of(6.31±1.31)%,which were lower than those of(6.02±0.41)mmol/L,(9.13±1.52)mmol/L and(7.82±1.03)%in the conventional group;the differences were statistically significant(P<0.05).Conclusion In the treatment of early and middle stage of diabetic nephropathy,ACEI combined with empagliflozin can effectively improve patients'clinical symptoms and urinary nephropathy indexes

关 键 词：糖尿病肾病 早中期 血管紧张素转换酶抑制剂 恩格列净 血糖 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]